This site is intended for healthcare professionals

Wegovy (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US.-Novo Nordisk

Read time: 1 mins
Last updated:7th Jun 2021
Published:6th Jun 2021
Novo Nordisk announced that the FDA has approved Wegovy (the brand name for once-weekly semaglutide 2.4 mg injection in the US) for chronic weight management. Wegovy is indicated as an adjunct to diet and exercise for chronic weight management in adults with obesity (initial BMI greater than 30 kg/m2) or overweight (initial BMI greater than 27 kg/m2) with at least one weight-related comorbidity.
Condition: Obesity
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest